Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its rivastigmine transdermal patch. This new treatment is intended for the management of symptoms associated with mild-to-moderate Alzheimer’s disease (AD).
Rivastigmine, classified as an acetylcholinesterase inhibitor, functions by decreasing the breakdown of acetylcholine. It achieves this by inhibiting the activity of both acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), which in turn raises the levels of acetylcholine within the central nervous system and enhances cognitive function in individuals suffering from AD. The transdermal patch offers the advantage of sustained and stable drug release over an extended period, contributing to stable blood drug concentration levels in patients and mitigating the side effects and efficacy variations associated with fluctuating drug concentrations. Additionally, the transdermal delivery method is designed to boost patient compliance, streamline medication management, and provide a suitable alternative for patients who may be non-responsive or physically unable to take oral medication. This follows a similar marketing approval granted to Luye Pharma Group’s (2186.HK) rivastigmine transdermal patch in China.- Flcube.com
